SI3277681T1 - Imidazolonilkinolini in njihova uporaba kot inhibitorji ATM-kinaze - Google Patents
Imidazolonilkinolini in njihova uporaba kot inhibitorji ATM-kinazeInfo
- Publication number
- SI3277681T1 SI3277681T1 SI201630345T SI201630345T SI3277681T1 SI 3277681 T1 SI3277681 T1 SI 3277681T1 SI 201630345 T SI201630345 T SI 201630345T SI 201630345 T SI201630345 T SI 201630345T SI 3277681 T1 SI3277681 T1 SI 3277681T1
- Authority
- SI
- Slovenia
- Prior art keywords
- imidazolonylquinolines
- kinase inhibitors
- atm kinase
- atm
- inhibitors
- Prior art date
Links
- BAHVJMJZUDCTPT-UHFFFAOYSA-N 4-quinolin-2-ylimidazol-2-one Chemical class O=C1N=CC(C=2N=C3C=CC=CC3=CC=2)=N1 BAHVJMJZUDCTPT-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15000968 | 2015-04-02 | ||
| EP16717560.3A EP3277681B1 (de) | 2015-04-02 | 2016-03-31 | Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren |
| PCT/EP2016/000542 WO2016155884A1 (de) | 2015-04-02 | 2016-03-31 | Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3277681T1 true SI3277681T1 (sl) | 2019-09-30 |
Family
ID=52814780
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201630345T SI3277681T1 (sl) | 2015-04-02 | 2016-03-31 | Imidazolonilkinolini in njihova uporaba kot inhibitorji ATM-kinaze |
| SI201631240T SI3560924T1 (sl) | 2015-04-02 | 2016-03-31 | Imidazolonilkinolini in njihova uporaba kot zaviralci ATM-kinaze |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201631240T SI3560924T1 (sl) | 2015-04-02 | 2016-03-31 | Imidazolonilkinolini in njihova uporaba kot zaviralci ATM-kinaze |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US10457677B2 (sl) |
| EP (3) | EP3277681B1 (sl) |
| JP (2) | JP6791873B2 (sl) |
| KR (2) | KR102652052B1 (sl) |
| CN (3) | CN111747952A (sl) |
| AU (3) | AU2016239270B2 (sl) |
| BR (1) | BR122019005502B1 (sl) |
| CA (1) | CA2981365A1 (sl) |
| DK (2) | DK3277681T3 (sl) |
| ES (3) | ES2946507T3 (sl) |
| HR (2) | HRP20191396T1 (sl) |
| HU (2) | HUE054745T2 (sl) |
| IL (3) | IL254714B (sl) |
| LT (2) | LT3277681T (sl) |
| MX (2) | MX2017012613A (sl) |
| PL (2) | PL3277681T3 (sl) |
| PT (2) | PT3560924T (sl) |
| RS (2) | RS62082B1 (sl) |
| RU (1) | RU2743343C2 (sl) |
| SG (2) | SG11201708065QA (sl) |
| SI (2) | SI3277681T1 (sl) |
| TR (1) | TR201911244T4 (sl) |
| WO (1) | WO2016155884A1 (sl) |
| ZA (1) | ZA201707423B (sl) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102652052B1 (ko) * | 2015-04-02 | 2024-03-27 | 메르크 파텐트 게엠베하 | 이미다졸로닐 퀴놀린 및 atm 키나아제 저해제로서의 이의 용도 |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| US11547703B2 (en) | 2017-02-27 | 2023-01-10 | Impact Therapeutics (Shanghai), Inc | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof |
| JOP20190209A1 (ar) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
| CA3087967A1 (en) | 2018-01-12 | 2019-07-18 | Prolynx Llc | Protocol for minimizing toxicity of combination dosages and imaging agent for verification |
| US20210353614A1 (en) * | 2018-03-14 | 2021-11-18 | Merck Patent Gmbh | Compounds and uses thereof to treat tumors in a subject |
| SG11202008739TA (en) | 2018-04-12 | 2020-10-29 | Bayer Ag | N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamide derivatives and the corresponding pyridine-carboxamide derivatives as pesticides |
| WO2019201283A1 (en) * | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
| CN110386932A (zh) * | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| GB201814487D0 (en) * | 2018-09-06 | 2018-10-24 | Cycle Pharmaceuticals Ltd | Cancer |
| CN109045042A (zh) * | 2018-09-21 | 2018-12-21 | 上海交通大学医学院附属上海儿童医学中心 | Atm抑制剂在制备抑制急性淋巴细胞性白血病复发的药物中的应用 |
| RU2771314C1 (ru) * | 2018-09-30 | 2022-04-29 | Медшайн Дискавери Инк. | Производные хинолинпирролидин-2-она и их применение |
| AU2020247451A1 (en) | 2019-03-27 | 2021-11-18 | Merck Patent Gmbh | Imidazolonylquinoline compounds and therapeutic uses thereof |
| MX2022001158A (es) * | 2019-07-30 | 2022-02-22 | Xrad Therapeutics Inc | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. |
| IL292613A (en) | 2019-11-01 | 2022-07-01 | Ares Trading Sa | Combined inhibition of pd-1, tgf-beta and atm along with radiotherapy for cancer treatment |
| AU2020398215A1 (en) * | 2019-12-04 | 2022-06-16 | Chdi Foundation, Inc. | ATM kinase inhibitors and compositions and methods of use thereof |
| WO2021139814A1 (zh) * | 2020-01-09 | 2021-07-15 | 南京明德新药研发有限公司 | 喹啉并咪唑类化合物及其应用 |
| WO2021197339A1 (zh) * | 2020-03-30 | 2021-10-07 | 南京明德新药研发有限公司 | 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用 |
| CN115916203A (zh) * | 2020-06-18 | 2023-04-04 | 默克专利股份公司 | 用于治疗病毒感染的化合物 |
| TW202216209A (zh) | 2020-06-24 | 2022-05-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及atm抑制劑之組合 |
| IL301412A (en) | 2020-09-18 | 2023-05-01 | Merck Patent Gmbh | A solid preparation containing a quinine derivative, its preparation and pharmaceutical preparations containing it |
| CA3184212A1 (en) * | 2020-09-21 | 2022-03-24 | Wei Zhong | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability |
| EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
| CN115232122B (zh) * | 2021-04-23 | 2024-05-31 | 石药集团中奇制药技术（石家庄）有限公司 | 炔类化合物及其制备和应用 |
| CN115716829B (zh) * | 2022-11-13 | 2024-05-31 | 药康众拓(江苏)医药科技有限公司 | 一种喹啉并咪唑酮联氘代吡唑类化合物及其应用 |
| US20240247014A1 (en) * | 2022-11-23 | 2024-07-25 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| EP1104760B1 (en) * | 1999-12-03 | 2003-03-12 | Pfizer Products Inc. | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents |
| GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| US8106202B2 (en) | 2005-03-21 | 2012-01-31 | Ferrer Internacional, S.A. | Method for making 1-substituted 1H-imidazo [4,5-C] quinolin-4-amine compounds and intermediates therefor |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| JP2009511481A (ja) * | 2005-10-06 | 2009-03-19 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 増強された治療特性を持つ、胃Ｈ＋，Ｋ＋−ＡＴＰａｓｅの重水素化阻害剤 |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| CA2676786C (en) | 2007-02-20 | 2015-01-27 | Novartis Ag | Imidazoquinolines as dual lipid kinase and mtor inhibitors |
| AU2009228797B2 (en) | 2008-03-26 | 2012-07-19 | Novartis Ag | 5imidazoquinolines and pyrimidine derivatives as potent modulators of VEGF-driven angiogenic processes |
| US8962629B2 (en) | 2008-06-10 | 2015-02-24 | Abbvie Inc. | Tricyclic compounds |
| EP3023097A1 (en) | 2008-10-01 | 2016-05-25 | Novartis AG | Smoothened antagonism for the treatment of hedgehog pathway-related disorders |
| AR076949A1 (es) * | 2009-06-04 | 2011-07-20 | Novartis Ag | Derivados de 1h-imidazo-(4,5-c)-quinolinona |
| US20100311714A1 (en) | 2009-06-04 | 2010-12-09 | Pascal Furet | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS |
| GB0919423D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| AU2011229542A1 (en) * | 2010-03-16 | 2012-11-08 | Merck Patent Gmbh | Morpholinylquinazolines |
| EP2585461B1 (en) * | 2010-06-28 | 2020-02-26 | Merck Patent GmbH | 2,4-diaryl-substituted [1,8]naphthyridines as kinase inhibitors for use against cancer |
| CN102372711B (zh) | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
| DE102010035744A1 (de) * | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| CN102399218A (zh) | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| CN103237544A (zh) | 2010-12-03 | 2013-08-07 | 诺华有限公司 | 药物组合物 |
| CN103012398B (zh) | 2011-09-19 | 2015-10-14 | 上海恒瑞医药有限公司 | 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
| WO2013154778A1 (en) | 2012-04-11 | 2013-10-17 | Dana-Farber Cancer Institute, Inc. | Host targeted inhibitors of dengue virus and other viruses |
| JP2015518888A (ja) | 2012-06-06 | 2015-07-06 | ノバルティス アーゲー | 腫瘍疾患を治療するための１７−アルファ−ヒドロキシラーゼ（ｃ１７，２０−リアーゼ）インヒビターと特定のｐｉ−３ｋインヒビターとの組み合わせ |
| NO2714752T3 (sl) * | 2014-05-08 | 2018-04-21 | ||
| KR102652052B1 (ko) * | 2015-04-02 | 2024-03-27 | 메르크 파텐트 게엠베하 | 이미다졸로닐 퀴놀린 및 atm 키나아제 저해제로서의 이의 용도 |
-
2016
- 2016-03-31 KR KR1020177031770A patent/KR102652052B1/ko active IP Right Grant
- 2016-03-31 ES ES21165573T patent/ES2946507T3/es active Active
- 2016-03-31 PT PT191729037T patent/PT3560924T/pt unknown
- 2016-03-31 LT LTEP16717560.3T patent/LT3277681T/lt unknown
- 2016-03-31 JP JP2017551589A patent/JP6791873B2/ja active Active
- 2016-03-31 CN CN202010644109.4A patent/CN111747952A/zh active Pending
- 2016-03-31 RU RU2017138100A patent/RU2743343C2/ru active
- 2016-03-31 PL PL16717560T patent/PL3277681T3/pl unknown
- 2016-03-31 SI SI201630345T patent/SI3277681T1/sl unknown
- 2016-03-31 TR TR2019/11244T patent/TR201911244T4/tr unknown
- 2016-03-31 WO PCT/EP2016/000542 patent/WO2016155884A1/de active Application Filing
- 2016-03-31 RS RS20210817A patent/RS62082B1/sr unknown
- 2016-03-31 CN CN201680031887.8A patent/CN107889488B/zh active Active
- 2016-03-31 DK DK16717560.3T patent/DK3277681T3/da active
- 2016-03-31 KR KR1020247009513A patent/KR20240044525A/ko active Search and Examination
- 2016-03-31 AU AU2016239270A patent/AU2016239270B2/en active Active
- 2016-03-31 RS RS20190993A patent/RS59139B1/sr unknown
- 2016-03-31 LT LTEP19172903.7T patent/LT3560924T/lt unknown
- 2016-03-31 MX MX2017012613A patent/MX2017012613A/es active IP Right Grant
- 2016-03-31 PT PT16717560T patent/PT3277681T/pt unknown
- 2016-03-31 BR BR122019005502-5A patent/BR122019005502B1/pt active IP Right Grant
- 2016-03-31 HU HUE19172903A patent/HUE054745T2/hu unknown
- 2016-03-31 SG SG11201708065QA patent/SG11201708065QA/en unknown
- 2016-03-31 CN CN202010644289.6A patent/CN111689963A/zh active Pending
- 2016-03-31 SG SG10202002181UA patent/SG10202002181UA/en unknown
- 2016-03-31 US US15/563,680 patent/US10457677B2/en active Active
- 2016-03-31 DK DK19172903.7T patent/DK3560924T3/da active
- 2016-03-31 EP EP16717560.3A patent/EP3277681B1/de active Active
- 2016-03-31 ES ES19172903T patent/ES2880626T3/es active Active
- 2016-03-31 HU HUE16717560A patent/HUE045477T2/hu unknown
- 2016-03-31 MX MX2020011558A patent/MX2020011558A/es unknown
- 2016-03-31 PL PL19172903T patent/PL3560924T3/pl unknown
- 2016-03-31 EP EP21165573.3A patent/EP3868761B1/de active Active
- 2016-03-31 EP EP19172903.7A patent/EP3560924B1/de active Active
- 2016-03-31 CA CA2981365A patent/CA2981365A1/en active Pending
- 2016-03-31 SI SI201631240T patent/SI3560924T1/sl unknown
- 2016-03-31 ES ES16717560T patent/ES2741853T3/es active Active
-
2017
- 2017-09-26 IL IL254714A patent/IL254714B/en active IP Right Grant
- 2017-11-01 ZA ZA2017/07423A patent/ZA201707423B/en unknown
-
2019
- 2019-03-14 US US16/353,559 patent/US10745399B2/en active Active
- 2019-08-01 HR HRP20191396 patent/HRP20191396T1/hr unknown
- 2019-12-17 IL IL271494A patent/IL271494B/en active IP Right Grant
-
2020
- 2020-06-24 US US16/910,438 patent/US10975075B2/en active Active
- 2020-06-25 AU AU2020204241A patent/AU2020204241B2/en active Active
- 2020-11-05 JP JP2020185129A patent/JP7111790B2/ja active Active
-
2021
- 2021-03-17 US US17/204,619 patent/US11608338B2/en active Active
- 2021-04-22 IL IL282584A patent/IL282584B/en unknown
- 2021-06-23 HR HRP20210981TT patent/HRP20210981T1/hr unknown
-
2022
- 2022-10-21 AU AU2022256215A patent/AU2022256215A1/en active Pending
-
2023
- 2023-03-01 US US18/116,094 patent/US20230203034A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE045477T2 (hu) | Imidazolonilkinolinok és ezek alkalmazása ATM kináz inhibitorként | |
| IL279258B (en) | tyrosine kinase inhibitors | |
| HK1256997A1 (zh) | Tyk2抑制劑及其用途 | |
| HK1248690A1 (zh) | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 | |
| EP3171874A4 (en) | Imidazolyl kinase inhibitors and uses thereof | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| SG10201913927VA (en) | Kinase inhibitors and uses thereof | |
| ZA201700021B (en) | Alk kinase inhibitor, and preparation method and use thereof | |
| HK1250926A1 (zh) | 抑制劑及其應用 | |
| IL251077A0 (en) | Integrin inhibitors and their use | |
| HK1250028A1 (zh) | 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途 | |
| IL251078B (en) | Integrin inhibitors and their use | |
| IL258690A (en) | Pyridone derivatives and their use as kinase inhibitors | |
| GB201609580D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201505975D0 (en) | Inhibitors and their uses | |
| GB201505971D0 (en) | Inhibitors and their uses | |
| GB201509381D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201505460D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201519382D0 (en) | Kinase inhibitors | |
| GB201519381D0 (en) | Kinase inhibitors | |
| GB201409661D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201405532D0 (en) | Novel compounds and their use as Kinase inhibitors |